Notably, a prescription that identifies only a patients name and drug product formulation is not sufficient to establish that the prescriber made the determination that the formulation would produce a significant difference from the commercially available drug product. According to the guidance, appropriate justification and documentation might include the following: No Dye X, patient allergy (if the comparable drug contains the dye) Liquid form, patient cant swallow tablet (if the comparable drug is a tablet) 6 mg, patient needs higher dose (if the comparable drug is only available in 5 mg dose)
Let's connect
Therefore, combining Gln metabolism inhibition and autophagy blockade with radiotherapy may represent a promising treatment strategy for PCa
Bsges a knlat a BioTech USA repertorjban, ahol tallsz tabletts, egy adagos folykony s akr literes folykony kiszerelst is
Lau A, Tian W, Whitman SA, Zhang DD
10.1016/j.immuni.2017.12.004 124 ZhaoQ.YangR.WangJ.HuD